| abstract |
The present invention relates to a transdermal therapeutic system comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer comprising rotigotine as an active ingredient, and (c) a release liner a mat wherein the self-adhesive matrix layer has a coating weight of from about 75 to about 400 grams per square meter and comprises a reservoir comprising from about 9 to about 25 percent by weight of rotigotine (by weight of the reservoir) The present invention relates to a kit comprising the two transdermal therapeutic systems of the present invention and a method for preparing the transdermal therapeutic system of the present invention. Further, the present invention relates to a transdermal therapeutic system comprising rotigotine as an active ingredient for treating Parkinson's disease, Parkinson's superimposition syndrome, depression, fibromyalgia and restless leg syndrome (restless leg) The use of a patient with syndrome, and the use of a transdermal therapeutic system comprising rotigotine as an active ingredient for the treatment or prevention of loss or cognitive impairment of dopaminergic neurons, which is administered percutaneously once or twice a week. In the case of tigotine, the transdermal therapeutic system comprises a backing layer, a solvent-based self-adhesive matrix layer containing rotigotine, and a release liner, and is adjusted to allow percutaneous administration An effective amount of rotigotine is given for at least 3 days. |